Immunome (IMNM) Liabilities and Shareholders Equity (2019 - 2026)

Immunome's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $619.8 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 80.86% year-over-year to $619.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 67.13% YoY) and the FY2025 annual result came in at $683.2 million, up 184.38% from the prior year.
• Liabilities and Shareholders Equity was $619.8 million for Q1 2026 at Immunome, down from $683.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $683.2 million in Q4 2025 and bottomed at $24.0 million in Q4 2022.
• A 5-year average of $225.1 million and a median of $240.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 58.49% — and 2024, when it jumped 614.89%.
• Immunome's Liabilities and Shareholders Equity stood at $24.0 million in 2022, then soared by 517.73% to $148.5 million in 2023, then soared by 61.73% to $240.2 million in 2024, then surged by 184.38% to $683.2 million in 2025, then fell by 9.28% to $619.8 million in 2026.
• Business Quant data shows IMNM's Liabilities and Shareholders Equity at $619.8 million in Q1 2026, $683.2 million in Q4 2025, and $299.4 million in Q3 2025.